【制药网 企业新闻】近日,艾伯维(AbbVie)宣布了一项重大战略决策,将以 21 亿美元现金收购临床阶段生物技术公司 Capstan Therapeutics。这一举措标志着艾伯维正式进军体内 CAR-T 疗法领域,有望为自身免疫性疾病及其他疾病的治疗带来革新。Capstan Therapeutics专注于开发前沿的体内细胞疗法。其核心技术是利用靶向脂质纳米颗粒(tLNP)递送 RNA,实现对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.